As of Thursday, June 26, Viking Therapeutics, Inc.’s VKTX share price has surged by 5.20%, which has investors questioning if this is right time to sell.

Investing.com - Cantor Fitzgerald has reiterated its Overweight rating and $104.00 price target on Viking Therapeutics (NASDAQ: VKTX), a $3.7 billion market cap biotech company, following its second ...